Detailed Narrative
Q2 FY26 Performance Overview
DOMS Industries reported a strong Q2 FY26, with consolidated operating revenues reaching ₹567.9 crores, marking a 24.1% year-on-year growth. This growth was primarily fueled by a 28% increase in domestic gross product sales and an 18.5% rise in international business. The company achieved a consolidated EBITDA of ₹99.5 crores, growing 15.8% YoY, with an EBITDA margin of 17.5%. Profit after tax (PAT) stood at ₹60.9 crores, up 13.4% YoY, resulting in a PAT margin of 10.7%.
GST 2.0 Transition and Market Impact
The government's GST 2.0 reforms, which slashed rates on key product categories, led to temporary disruptions in September, including inventory clearance and order postponement. Products impacted by the GST transition (from 12%/5% to 0%) constitute 45% of FY25 sales, with baby hygiene (from 12% to 5%) making up 6%. Management estimates that sales could have been 3-4% higher without this transition impact. Despite the disruption, the company managed to maintain its EBITDA margins, as pricing adjustments were made to offset changes in input tax credit eligibility.
Expansion Initiatives and Capacity Build-up
The company is progressing steadily on its 44-acre expansion project, with the first building expected to be in possession by Q4 FY26 and commercial production commencing in Q1 FY27. This facility will primarily be dedicated to pencil capacity expansion. Additionally, brownfield initiatives are ongoing, particularly in the adhesive segment and office supplies, where significant capacity additions have already driven growth. Current capacity utilization for core scholastic stationery and art materials is upwards of 95%, while installed capacity for office supplies/hobby/craft has reached over 75%.
Product Portfolio and Marketing Efforts
DOMS continues to expand its product portfolio across all segments, introducing new scholastic art materials, kits, combo packs, office supplies, and scholastic stationery, including a new range of mechanical pencils. The baby hygiene business (Uniclan Healthcare) also yielded positive results. The company engaged in consumer connect initiatives, including a strategic partnership with Kaun Banega Crorepati, primarily for overall brand building and aspirational value, rather than specific product promotion.
Regional Sales Dynamics
While overall domestic sales grew strongly, there was a divergence in regional performance, with South India showing higher growth compared to East India. Management attributed this to the timing of Durga Puja in September, which caused a temporary standstill in the Eastern region for about 10 days. They emphasized that regional performance should be viewed on a full-year basis to get an accurate picture, as festive periods can distort quarterly data.
Operating Margins and Cost Management
The company successfully maintained its EBITDA margin at 17.5%, within its guided range of 16.5-17.5%, demonstrating operational efficiencies. Employee costs increased as a percentage of sales due to an overall increase in workforce for sales and production teams, in anticipation of increased volumes and new plant ramp-up. Management stated that the ramp-up of new capacities is not expected to significantly impact margins, as the company's philosophy is to maintain consistent margins across products.
Future Outlook and Strategic Focus
DOMS remains optimistic about the second half of the year, expecting to achieve its full-year growth guidance of 18-20%. The company plans to continue investing in capacity building for the next 3-5 years, aiming for ₹3 in revenue for every ₹1 invested in capacity. The focus remains on leveraging its widespread product portfolio, expanding market penetration, and capitalizing on demand opportunities, supported by government initiatives like GST rate reductions and income tax cuts.